The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Evaluating the reliability of isatuximab OBI: pooled safety analysis from IRAKLIA, IZALCO & TCD15484
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the results of a pooled safety analysis across three trials, IRAKLIA (NCT05405166), IZALCO (NCT05704049), and TCD15484 (NCT04045795), which evaluated the reliability of an on-body injector (OBI) for subcutaneous drug administration in multiple myeloma. Prof. Leleu highlights that the analysis showed the OBI to be a trustworthy device with a favorable safety profile, even with long-term exposure, and notes that patients tend to like the device, which also offers an automated and ecologically responsible solution. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s a technical advance which is very interesting. It’s great to see that we still make progress in how to improve the quality of administering the treatment to the patients safer, particularly considering that the treatment is very long and so if you give three, four, five years of a treatment to the patients, you need to make sure five years later it does not bother too much the quality of life of the patients being on treatment...
It’s a technical advance which is very interesting. It’s great to see that we still make progress in how to improve the quality of administering the treatment to the patients safer, particularly considering that the treatment is very long and so if you give three, four, five years of a treatment to the patients, you need to make sure five years later it does not bother too much the quality of life of the patients being on treatment. And so what I think this OBI, on-body injector, through all the studies you mentioned, and there are even more, ISASOCUT etc, we’re showing is that it seems you can trust the device, it seems the patients like it initially and like it two years later, it seems the safety profile is not compromised with long-term exposure. It’s now, if you look at it, like I want to be ecologically responsible, there is no battery, it’s an automated system, it takes into consideration the thickness of your skin, because you don’t have the same skin, I don’t know, I mean, my experience is it’s incredibly genius, it’s like five years ago, you would have told me, okay, we’re gonna develop a new subcutaneous formulation, I would not have trusted it’s possible, and here you have this OBI, and now it’s possible, so I think it’s great that we improve the drug for the patients, but we also can improve the formulation of those drugs for the patients. I think it’s an amazing experience, and it’s an amazing device, and it’s an amazing idea, and the people who had this idea are really smart people.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
